Book Online Consultation

OUTCOMES OF SOF, RIBA AND PEG-INF THERAPY FOR THE TREATMENT OF CHRONIC HEP-C G3 TREATMENT NAIVE PATIENTS

Posted on

SIDRA GILL, NOSHEEN YOUSAF, FAIZA IRFAN, AMMARA NAWAZ, UZMA FEYAZ QAZI, MUZZAFFAR GILL MAROOF INTERNATIONAL HOSPITAL, ISLAMABAD, PAKISTAN

Background: Sovaldi, Ribavirin and PEG-Interferon is gold standard therapy for chronic HEP-C patients. It

is recommended both for treatment naive and experienced patients. We evaluated the safety and

efficacy of this combination in naïve chronic HEP-C G3 patients.

Methods: We prospectively enrolled 50 chronic HEP-C G3 treatment naïve patients.

Patients with de-compensated cirrhosis, platelets count<100, portal vein size >13 mm on ultrasound in

size were excluded.

Eligible patients were enrolled to receive Sovaldi 400mg daily, Ribavirin 10 mg/Kg body weight and

Pegylated interferon 1.5 UCG/KG body weight for 12 weeks.

Patients were seen in outpatient 4-weekly basis. They had baseline CBC, TSH, Blood Sugar, HCV

Genotype, and HCVPCR quantitative. Each patient had CBC at every 4 weeks. RVR at treatment week 4,

and ETR (End of Treatment) at weeks 12 were defined by HCV RNA <25 IU/mL.

Results: This is our ongoing study we are presenting interim analysis of 50 patients who have

completed 12 weeks of treatment.

Out of 50 patients 75% were male, 25 % were female with median age 48 years. 48 patients out of 100

(96%) were PCR negative at week 4 and 96% were PCR negative at week 12 respectively. Two patients

did not achieve RVR, and they did not achieve ETR either.

The most common AEs were nausea, fatigue, dizziness.

Conclusions: Sofosbuvir + Ribavirin+PEG INF in HCV-G3 infected patients are very effective treatment.

Most patients achieved rapid Virologic response without any major side effects. These patients are

under regular review to monitor SVR.




PROF. MUZAFFAR LATIF GILL is providing telemedicine services to patients, due to Coronavirus epidemic Patients are Wellcome to visit IGA

They will be evaluated by medical officer then they will have video link with professor Muzaffar Gill

Timings are from 12 to 5pm

Best wishes